Goodrx Holdings, Inc. ((GDRX)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GoodRx Holdings used its latest earnings call to reassure investors that its transformation is gaining traction even as its legacy prescription transactions business weakens. Management acknowledged a sharp 24% drop in PTR revenue and stubborn unit-economics pressure but stressed that Pharma Direct, subscriptions, and e-commerce scale are offsetting these headwinds and supporting stronger margins and higher guidance.
Q1 Revenue and Profitability
GoodRx reported first-quarter 2026 revenue of $194 million and adjusted EBITDA of $58.3 million, translating to a robust 30% adjusted EBITDA margin. The company framed this profitability as evidence that its diversified model can deliver solid earnings even while core PTR volumes face structural pressure.
Strong Pharma Direct Growth
Pharma Direct remained the star performer, with revenue surging 82% year over year to $52.2 million in the quarter. Management now expects Pharma Direct to grow more than 50% for full-year 2026, supported by over 125 self-pay programs that deepen relationships with manufacturers and expand access for cash-pay patients.
Raised Full-Year Guidance
On the back of Pharma Direct outperformance, GoodRx raised its 2026 outlook to $765 million–$785 million in revenue and at least $235 million in adjusted EBITDA. Executives emphasized that stronger mix from higher-margin growth areas underpins confidence in both top-line resilience and sustained double-digit EBITDA margins.
Subscription Expansion and Revenue Growth
Subscription revenue climbed 16% year over year to $24.4 million, with condition-specific offerings, including GoodRx for weight loss, returning to growth. The company also nudged average revenue per subscription higher from about $10 to roughly $11, signaling that targeted programs can support richer pricing and engagement.
Rx Marketplace Operational Scalability
GoodRx highlighted improved operational scalability in its Rx marketplace following expansion of its e-commerce retail network. Order volume and total claims more than doubled quarter over quarter, while monthly active consumers stabilized sequentially at around 5.3 million, suggesting the platform can handle rising throughput even without user growth.
Wegovy Pill Launch Contribution
Early GLP-1 momentum is reinforcing GoodRx’s relevance in high-profile drug launches. Management cited third-party data indicating the platform facilitated roughly one-third of Wegovy Pill transactions during the first two months post-launch, underscoring its role as a key channel for patients navigating new obesity therapies.
Retail and Distribution Progress
The company has now secured direct contracts with 9 of the top 10 retail pharmacies nationwide, tightening its grip on distribution. It is also working to route pharma direct net-pricing claims directly to pharmacy counters, an initiative designed to streamline the consumer experience and enhance marketplace economics over time.
Strategic Partnerships and Program Launches
GoodRx continued to broaden its pharma relationships with new collaborations and branded storefronts. Recent additions include Viatris-supported discounts on 17 branded medications and Pfizer programs spanning more than 30 drugs, along with incremental traffic from TrumpRx activity, all aimed at expanding reach to new patient segments.
Marketing Efficiency Early in Year
Subscription momentum was achieved despite lower marketing spend year over year in the first quarter. Management pointed to improved organic engagement and better return on marketing as evidence that brand recognition and product fit are increasingly doing the heavy lifting for customer acquisition.
Decline in Prescription Transactions Revenue
Prescription transactions revenue fell to $113.7 million in Q1, a steep 24% decline from a year earlier. The drop reflects lingering unit-economics pressure in the legacy PTR business and tough comparisons as the company laps unusually strong volumes related to programs in 2025.
Continued Pressure and Uncertainty on PTR
Executives warned that PTR pressure is likely to persist through 2026 as pricing dynamics and competitive behavior remain challenging. Their internal models assume potential ongoing erosion in prescription transactions, though at a more moderated or flattened pace compared with the recent contraction.
MAC Growth Limited
Monthly active consumers held roughly flat sequentially at about 5.3 million, stabilizing but not expanding. Management acknowledged that they are modeling some downside risk to MAC later this year, highlighting that user growth remains a watch point despite strength in newer revenue streams.
Past ISP Volume Lapping Impact
The company clarified that some of the year-over-year weakness reflects lapping of non-recurring volume from an integrated savings program in 2025. This one-off contribution inflated the prior-year baseline, making current PTR trends look harsher even as the underlying business transitions to a more diversified model.
No Material Benefit Yet from Surescripts Partnership
Five months after announcing their partnership with Surescripts, management reported no material benefit yet to volumes or revenue. They emphasized that the collaboration is not embedded in current guidance, framing any future uplift as potential upside rather than a near-term driver.
Increasing Competitive and Macro Headwinds
GoodRx flagged intensifying competition in GLP-1 and direct-to-consumer markets as more manufacturers, telehealth firms, and pharmacies vie for patients. Macro and regulatory factors, including shifts in insurance coverage and subsidy programs, add further uncertainty to demand patterns and pricing power.
Revenue Mix Shift and Unit Economics
The company is deliberately shifting revenue from higher-dollar PTR into Pharma Direct and subscriptions, aiming for a more durable mix. While management acknowledged that this can compress unit economics in some areas and pressure revenue per transaction, they argue the trade-off enhances long-term resilience and strategic leverage.
Lack of Consolidated Prescription Metric Disclosure
Investors seeking a single lens on prescription volume growth may be frustrated by the lack of a consolidated “total prescriptions processed” metric. Management said they do not currently disclose such a figure, limiting visibility into how aggregate prescription touches evolve as revenue spreads across multiple buckets.
Potential Price Volatility Risk
Pricing for GLP-1s and other programs remains a swing factor, with management noting that prices can fluctuate as competition and multisource launches emerge. Potential declines in drug prices later this year could weigh on revenue per prescription, adding another variable for investors to monitor.
Guidance and Forward-Looking Outlook
Looking ahead, GoodRx’s raised 2026 guidance signals confidence that Pharma Direct, subscriptions, and e-commerce can more than offset weakness in legacy PTR. The company is betting that continued expansion of self-pay programs, retail contracts, and partner storefronts will support mid- to high-single-digit growth and sustained profitability.
GoodRx’s latest earnings call painted a picture of a business in transition, balancing legacy erosion with rapid growth in newer lines. The company’s ability to expand Pharma Direct, deepen partnerships, and maintain a 30% adjusted EBITDA margin offers investors reasons for cautious optimism even as PTR and macro risks remain front and center.